Redeye: Formpipe - Renewed Go-To-Market to Accelerate Lasernet Growth
Redeye reduces its Base Case slightly despite cutting its 2024-2025 EBIT forecasts following a soft Q1 report. While the issues in Public Deliveries are most likely temporary, the relatively low Private ACV is a greater concern. However, we are encouraged to see management's new initiatives to accelerate Lasernet’s growth.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/